Heinz Laubli

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 129 publications

α2,3-sialylation on human naïve T cells restrains bispecific engager-mediated anti-tumor immunity.

α2,3-sialylation on human naïve T cells restrains bispecific engager-mediated anti-tumor immunity.

Journal: bioRxiv : the preprint server for biology
Published: August 20, 2026

Author Correction: The evolving role of cytokines for CAR-T cell manufacturing and beyond.

Author Correction: The evolving role of cytokines for CAR-T cell manufacturing and beyond.

Journal: Nature biomedical engineering
Published: August 10, 2026

Cytotoxic CD39+ tumor-associated NK cells respond to NKG2A blockade in lung cancer.

Cytotoxic CD39+ tumor-associated NK cells respond to NKG2A blockade in lung cancer.

Journal: Science immunology
Published: June 05, 2026

Tumor Genomic Profiles Associated with Clinical Benefit from Immune Checkpoint Inhibitor Therapy - An Exploratory Analysis of the INFINITY Precision Oncology Registry.

Tumor Genomic Profiles Associated with Clinical Benefit from Immune Checkpoint Inhibitor Therapy - An Exploratory Analysis of the INFINITY Precision Oncology Registry.

Journal: OncoTargets and therapy
Published: April 01, 2026

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal: Journal of hematology & oncology
Published: March 25, 2026

Fucosylation in cancer and its role in anti-tumor immunity.

Fucosylation in cancer and its role in anti-tumor immunity.

Journal: European journal of cell biology
Published: March 20, 2026

A Th17 signature correlates with response to dual CTLA-4 and PD-1 blockade in metastatic renal cell carcinoma.

A Th17 signature correlates with response to dual CTLA-4 and PD-1 blockade in metastatic renal cell carcinoma.

Journal: medRxiv : the preprint server for health sciences
Published: November 19, 2025

Mechanisms of resistance to adoptive cell therapy with tumor-infiltrating lymphocytes.

Mechanisms of resistance to adoptive cell therapy with tumor-infiltrating lymphocytes.

Journal: Expert review of clinical immunology
Published: November 10, 2025

Mixed-methods process evaluation of ctDNA use to guide decision-making in patients with advanced solid cancers: study protocol for a substudy of the LIQPLAT trial.

Mixed-methods process evaluation of ctDNA use to guide decision-making in patients with advanced solid cancers: study protocol for a substudy of the LIQPLAT trial.

Journal: BMJ open
Published: October 28, 2025

Tumor-Infiltrating Lymphocyte Adoptive Cell Therapy With PD-1 Blockade in Pediatric Chemotherapy-Resistant Osteosarcoma.

Tumor-Infiltrating Lymphocyte Adoptive Cell Therapy With PD-1 Blockade in Pediatric Chemotherapy-Resistant Osteosarcoma.

Journal: Pediatric blood & cancer
Published: October 24, 2025

Exacerbation of demyelinating polyneuropathy after adoptive cell therapy with tumour-infiltrating lymphocytes by metastatic melanoma.

Exacerbation of demyelinating polyneuropathy after adoptive cell therapy with tumour-infiltrating lymphocytes by metastatic melanoma.

Journal: Swiss medical weekly
Published: October 14, 2025

The Perception and Development of Virtual Multidisciplinary Teams in Oncology in the Post-COVID-19 Era.

The Perception and Development of Virtual Multidisciplinary Teams in Oncology in the Post-COVID-19 Era.

Journal: Healthcare (Basel, Switzerland)
Published: October 01, 2025
Showing 1-12 of 129

Last Updated: 09/26/2026